Welcome to our dedicated page for TFF Pharmaceuticals news (Ticker: $TFFP), a resource for investors and traders seeking the latest updates and insights on TFF Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TFF Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TFF Pharmaceuticals's position in the market.
TFF Pharmaceuticals, Inc (Nasdaq: TFFP) closed a public offering, raising approximately $4.8 million by selling shares and warrants. The company plans to use the net proceeds for general corporate purposes and working capital.
TFF Pharmaceuticals, Inc. announced a public offering of 1,665,219 shares of common stock and warrants, priced at $2.875 per share, with gross proceeds estimated at $4.8 million. The Company plans to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on May 1, 2024.
TFF Pharmaceuticals has released Phase 2 data from Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. Results show TFF TAC can prevent rejection at lower doses than oral tacrolimus, reducing systemic exposures and toxicities. Gene expression data indicate TFF TAC normalizes rejection-related genes, potentially improving efficacy and safety post-transplant.
